Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 15/20 | 0.55 |
| ▸ | VEGFA | P15692 | 3/20 | 0.46 |
| ▸ | FLT1 | P17948 | 3/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.46 |
| ▸ | EGLN3 | Q9H6Z9 | 3/20 | 0.46 |
| ▸ | POLQ | O75417 | 1/20 | 0.39 |
| ▸ | TET3 | O43151 | 1/20 | 0.39 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.39 |
| ▸ | ASPH | Q12797 | 1/20 | 0.39 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.39 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.39 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 0.39 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.39 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.39 |
| ▸ | CTSA | P10619 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24257681 | 0.89 | CNR2 (0.45) | CNR2VEGFAFLT1EGLN1EGLN3 | |
| SCHEMBL24257532 | 0.83 | CNR2 (0.48) | CNR2VEGFAFLT1EGLN1EGLN3 | |
| SCHEMBL30453143 | 0.83 | CNR2 (0.48) | CNR2VEGFAFLT1EGLN1EGLN3 | |
| SCHEMBL29772956 | 0.82 | EGLN1 (0.68) | CNR2VEGFAFLT1EGLN1EGLN3 | |
| SCHEMBL1921669 | 0.82 | EGLN1 (0.68) | CNR2VEGFAFLT1EGLN1EGLN3 | |
| SCHEMBL24257568 | 0.78 | EGLN1 (0.58) | CNR2VEGFAFLT1EGLN1EGLN3 | |
| SCHEMBL26260456 | 0.78 | PIN1 (0.50) | VEGFAFLT1EGLN1EGLN3TET3 | |
| SCHEMBL24257633 | 0.78 | EGLN1 (0.65) | VEGFAFLT1EGLN1EGLN3TET3 | |
| SCHEMBL30546863 | 0.76 | EGLN1 (0.41) | CNR2VEGFAFLT1EGLN1EGLN3 | |
| SCHEMBL24257523 | 0.76 | EGLN1 (0.41) | CNR2VEGFAFLT1EGLN1EGLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| CN-116670131-A | PHD inhibitor compounds, compositions, and methods of use | 阿克比治疗有限公司 | 2023-08-29 | — | — | CN | disclosed |
| EP-4196466-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | Akebia Therapeutics Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
| WO-2022036188-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | HIF1AN, EGLN3, PHF20 | CNR2 4211/4885VEGFA 1862/4885FLT1 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.